Streeting has also promised to reduce the time it takes to get clinical trials approved by cutting red tape, pointing out ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical and economic uncertainty. We’ve seen recent tariff policy changes ...

Dan Gandor has spent his whole career pioneering digital techniques for pharma marketing and creating centres of excellence at pharma companies like Takeda and AbbVie. Last month, he joined ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The FDA has introduced a stricter set of policies around COVID-19 vaccines, including a clinical trial requirement for new shots intended for widespread use. Any vaccine intended for use in people ...

Using mRNA to stop HIV from hiding away in white blood cells could be the key to developing a way to eradicate the infection, rather than simply managing viral levels in the body. The tantalising ...

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a treatment for multiple myeloma. The Ministry of Health, Labour and Welfare ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

A banner from Moderna's 2023 campaign to highlight the power of mRNA to transform medicine. In January, Moderna was celebrating a $590 million contract with the US government to develop pandemic ...